Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$4.41 -2.4%	$3.93	$3.21 ▼ $7.18	$1.06B	0.6	4.42 million shs	3.25 million shs
DYN Dyne Therapeutics	$9.02 -4.0%	$11.19	$6.36 ▼ $47.45	$1.03B	1.08	1.92 million shs	1.58 million shs
OCUL Ocular Therapeutix	$11.33 -0.4%	$8.80	$5.79 ▼ $11.78	$1.80B	1.43	1.44 million shs	2.13 million shs
TRDA Entrada Therapeutics	$6.26 -1.9%	$7.47	$6.23 ▼ $21.79	$237.59M	-0.11	134,719 shs	118,687 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-2.43%	-1.78%	+22.16%	-8.51%	-23.30%
DYN Dyne Therapeutics	-4.04%	+4.40%	-16.33%	+10.40%	-78.25%
OCUL Ocular Therapeutix	-0.44%	+2.72%	+36.01%	+54.99%	+41.63%
TRDA Entrada Therapeutics	-1.88%	-4.43%	-10.95%	-23.00%	-63.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.0136 of 5 stars	3.5	1.0	4.4	2.1	2.5	0.6
DYN Dyne Therapeutics	3.8882 of 5 stars	4.5	3.0	0.0	3.0	4.2	0.0
OCUL Ocular Therapeutix	3.6443 of 5 stars	3.5	2.0	4.1	0.6	2.5	0.0
TRDA Entrada Therapeutics	3.1899 of 5 stars	3.6	1.0	0.0	2.3	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$10.89	146.91% Upside
DYN Dyne Therapeutics	3.00	Buy	$40.63	350.39% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.33	52.99% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	310.01% Upside

Current Analyst Ratings Breakdown

Latest TRDA, OCUL, DYN, and ARDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/11/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/26/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/25/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2025	DYN Dyne Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/18/2025	DYN Dyne Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/18/2025	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$46.00 ➝ $32.00
6/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/11/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$37.00
6/2/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$60.00 ➝ $34.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$333.61M	3.16	N/A	N/A	$0.73 per share	6.04
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.19 per share	N/A
OCUL Ocular Therapeutix	$63.72M	28.33	N/A	N/A	$2.01 per share	5.64
TRDA Entrada Therapeutics	$210.78M	1.13	$1.59 per share	3.94	$11.46 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.22	N/A	14.23	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
DYN Dyne Therapeutics	-$317.42M	-$3.59	N/A	N/A	N/A	N/A	-52.83%	-48.84%	8/11/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.15	N/A	N/A	N/A	-323.09%	-59.92%	-41.98%	8/6/2025 (Estimated)
TRDA Entrada Therapeutics	$65.63M	$0.81	7.73	N/A	N/A	14.39%	5.84%	4.61%	8/12/2025 (Estimated)

Latest TRDA, OCUL, DYN, and ARDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	TRDA Entrada Therapeutics	-$0.86	N/A	N/A	N/A	$8.17 million	N/A
8/11/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ARDX Ardelyx	-$0.12	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	N/A	N/A	N/A	$13.12 million	N/A
5/8/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	-$1.05	-$0.17	-$1.05	N/A	N/A
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.04	4.12	3.81
DYN Dyne Therapeutics	N/A	20.35	20.35
OCUL Ocular Therapeutix	0.26	10.22	10.14
TRDA Entrada Therapeutics	N/A	21.88	21.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
DYN Dyne Therapeutics	96.68%
OCUL Ocular Therapeutix	59.21%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
DYN Dyne Therapeutics	14.14%
OCUL Ocular Therapeutix	2.30%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
DYN Dyne Therapeutics	100	113.67 million	97.59 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	155.64 million	Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.88 million	Optionable

TRDA, OCUL, DYN, and ARDX Headlines

Recent News About These Companies

5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k

July 13, 2025 | investing.com

Entrada therapeutics (TRDA) director Parmar sells $202k in stock

July 13, 2025 | investing.com

Ventures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 12, 2025 | insidertrades.com

Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,935 Shares of Stock

July 11, 2025 | marketbeat.com

Ventures V. L.P. 5Am Sells 20,065 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 11, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Sells $202,500.00 in Stock

July 11, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Shares Down 3.6% - Should You Sell?

July 8, 2025 | marketbeat.com

Entrada Therapeutics (TRDA) 10% owners sell $866k in stock

July 3, 2025 | investing.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 Shares

July 2, 2025 | insidertrades.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar Sells 75,000 Shares

July 1, 2025 | marketbeat.com

Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,422 Shares of Stock

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 18,578 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 19,265 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar Sells 25,000 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 55,735 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Upgraded to "Hold" at Wall Street Zen

June 27, 2025 | marketbeat.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29, 2025 | morningstar.comM

Entrada Therapeutics to start DMD trial in Q3 2025

May 29, 2025 | investing.com

Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025

May 29, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom

TRDA, OCUL, DYN, and ARDX Company Descriptions

Ardelyx NASDAQ:ARDX

$4.41 -0.11 (-2.43%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.39 -0.02 (-0.45%)

As of 07/18/2025 07:55 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics NASDAQ:DYN

$9.02 -0.38 (-4.04%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$9.09 +0.07 (+0.73%)

As of 07/18/2025 07:50 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Ocular Therapeutix NASDAQ:OCUL

$11.33 -0.05 (-0.44%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.63 +0.30 (+2.68%)

As of 07/18/2025 05:20 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Entrada Therapeutics NASDAQ:TRDA

$6.26 -0.12 (-1.88%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$6.27 +0.01 (+0.16%)

As of 07/18/2025 04:04 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time